Life Sciences Tools and Services
Company Overview of STEMCELL Technologies Canada Inc.
STEMCELL Technologies Canada Inc. develops cell culture media, cell separation systems, instruments, and other reagents to support research in the fields of immunology, hematology, neuroscience, mesenchymal stem cell, stem cell, and epithelial cell biology. It offers antibodies, buffers and solutions, cell culture media and supplements, cell dyes and detection assay kits, cell isolation products, cell storage media, cultureware and general supplies, cytokines, density gradient media, ELISAs, instruments and software, laboratory equipment, matrices and substrates, primary and cultured cells, small molecules, standardization tools, and tissue and cell culture dissociation reagents. The company...
570 West Seventh Avenue
Vancouver, BC V5Z 1B3
Founded in 1993
Key Executives for STEMCELL Technologies Canada Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2016.
STEMCELL Technologies Canada Inc. Key Developments
Cellular Dynamics International Signs Distribution Deal with STEMCELL Technologies
Apr 18 17
Cellular Dynamics International announced that, it has signed a distribution agreement with STEMCELL Technologies. Under the terms of the agreement, STEMCELL Technologies will distribute CDI’s iCell® catalog of products in North America, Europe, and Singapore, with other countries under consideration. CDI’s iCell products are differentiated human induced pluripotent stem cell (iPSC)-derived cells, which include cardiomyocytes, hepatocytes, and others, totaling up to 12 cell types.
STEMCELL Technologies Opens New Office and Laboratories in Cambridge, UK
Jan 31 17
STEMCELL Technologies UK has recently celebrated the grand opening of their Cambridge-based facility. Founded by Dr. Allen Eaves, STEMCELL provides specialized reagents and tools that support research on cancer and other diseases, as well as cell therapy and regenerative medicine globally. Cambridge is a leading global hub for stem cell research. This, combined with its proximity to STEMCELL’s customers in the UK and Europe, makes the location a natural choice for continued investment by the company. STEMCELL recently took possession of an 18,000 square foot building located in the Cambridge Research Park. STEMCELL has now consolidated existing UK staff into the facility, which at full capacity will house a substantial Research and Development group, as well as Sales, Marketing and other support staff. A major focus of the new facility will be a Education and Teaching Lab. STEMCELL offers several standard and customized training courses and workshops, which are currently hosted within collaborating academic lab facilities. The multi-day, interactive courses are designed to help researchers develop expertise in protocols and techniques supported by STEMCELL’s products. Several of these world-class courses will soon be offered in the new Cambridge facility, making them more accessible to researchers in the UK and Europe.
STEMCELL Technologies Signs Exclusive License Agreement with Cincinnati Children’s for Stem Cell-Derived Organoid Technology
Dec 19 16
STEMCELL Technologies Inc. announced that has signed an exclusive license agreement with Cincinnati Children’s Hospital Medical Center to commercialize its fundamental technology for generating gastrointestinal organoids from pluripotent stem cells (PSCs). This agreement grants STEMCELL a license to novel methods for generating organoid models and to develop cell culture media and tools that would enable scientists to create organoids from PSCs in their own laboratories. The technology licensed from Cincinnati Children’s describes methods for generating gastrointestinal organoids, including intestinal and stomach, from human PSCs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|